<DOC>
	<DOCNO>NCT01327950</DOCNO>
	<brief_summary>This national , prospective , multi-center , non-randomized study evaluate long-term efficacy integrity EPICTM Nitinol Vascular Stent System Superficial Femoral Artery ( SFA ) lesion . A total 100 patient include approximately 10 site . The study design demonstrate EPIC Nitinol Vascular Stent System non- inferior publish patency rate find literature . This non-inferiority establish prove true rate EPICTM Nitinol Vascular Stent System high 82 % minus 10 % delta .</brief_summary>
	<brief_title>Efficacy EPIC Nitinol Vascular Stent System Superficial Femoral Artery ( SFA ) Lesions</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>General Patient present stenosis , restenosis PTA ( adjunct therapy , exclude stent stent graft ) occlusion native superficial femoral artery ( SFA ) , SFA proximal popliteal artery , suitable primary stenting ; Patient score 2 5 follow Rutherford classification ; Patient willing comply specify followup evaluation specify time ; Patient least 18 year old ; − Patient ( legal representative ) understand nature procedure provide write informed consent prior enrollment study ; Patient eligible treatment selfexpanding EPIC Nitinol Vascular Stent System Notes : If patient contralateral peripheral lesion , lesion treat nontarget lesion study procedure If patient ipsilateral iliac lesion , lesion treat non target lesion , treatment conduct target lesion treatment ( procedure previous procedure ) , successful result define less 30 % residual diameter stenosis Angiographic Target lesion ( ) location situate native SFA SFA proximal popliteal artery , proximal point least 1cm origin deep femoral artery distal point least 3cm proximal knee joint , measure ipsilateral oblique view proximal lesion straight posterioanterior ( PA ) view distal lesion ; Evidence least 50 % stenosis , restenosis PTA ( adjunct therapy , exclude stent stent graft ) occlusion target lesion ; Target lesion ( ) total length minimally 4cm maximally 11cm amenable treatment single stent ; Target vessel diameter visually estimate &gt; 4mm &lt; 6.5mm There angiographic evidence least onevesselrunoff foot General Presence another stent stent graft target vessel place previous procedure ; Presence aortic thrombosis significant common femoral ipsilateral stenosis ; Previous bypass surgery limb ; − Necessity treat target vessel one EPICTM stent ; Patients antiplatelet therapy , anticoagulant thrombolytic drug contraindicate ; Patient bleed diathesis , coagulopathy , know hypercoagulable condition refuse blood transfusion ; Patients know hypersensitivity nickeltitanium ; Female patient child bear potential take adequate contraceptive currently breastfeed ; Life expectancy less twelve month ; Ipsilateral iliac treatment target lesion procedure residual stenosis &gt; 30 % ipsilateral iliac treatment conduct target lesion procedure ; Use cut balloon , score balloon , thrombectomy , arthrectomy , brachytherapy laser device procedure ; Any patient consider hemodynamically unstable onset procedure ; Patient currently participate another investigational drug device study complete entire follow period ; Patient present one follow comorbid condition : hemodialysis , elevate creatine level ( &gt; 2.5mg/dl ) , recent MI hemorrhagic stroke occurrence ( within 30 day ) . Angiographic Inability cross target lesion mean exchangeable guidewire reenter true vessel lumen distal lesion site ; Presence significant ( minimally 50 % ) stenosis occlusion ipsilateral common femoral artery ; Aneurysm locate level tobetreated artery ; − Patients exhibit persistent acute intraluminal thrombus propose lesion site ; − Perforation ( evidence extravasation contrast medium ) , dissection injury access target vessel require additional stenting surgery prior start index procedure ; Focal popliteal artery disease absence femoral disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Percutaneous treatment</keyword>
	<keyword>Superficial Femoral Artery lesion</keyword>
	<keyword>EPIC Nitinol Vascular Stent System</keyword>
</DOC>